Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

PURPOSE: Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved progressi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Edelman, Martin J., Wang, Xiaofei, Hodgson, Lydia, Cheney, Richard T., Baggstrom, Maria Q., Thomas, Sachdev P., Gajra, Ajeet, Bertino, Erin, Reckamp, Karen L., Molina, Julian, Schiller, Joan H., Mitchell-Richards, Kisha, Friedman, Paula N., Ritter, Jon, Milne, Ginger, Hahn, Olwen M., Stinchcombe, Thomas E., Vokes, Everett E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5493050/
https://ncbi.nlm.nih.gov/pubmed/28489511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.3743
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados